Physician Resources
Recently Added |view more
News
Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.
In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent ...
News
Fox Chase – Temple Urologic Institute at AUA 2026
Visit the Fox Chase-Temple Urologic Institute Booth #2464 in the Science & Technology Hall.
Symposium
24th Annual Highlights of the 2025 San Antonio Breast Cancer Symposium
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this education program is designed to help medical, radiation, and surgical oncologists, gynecologists, and radiologists translate the ...
News
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).
News
Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
News
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new ...
News
Combined Tests Could Reduce Unnecessary Bladder Removal
Combining a visual inspection of the bladder with a blood test to check for the presence of circulating tumor DNA can accurately predict which bladder cancer patients still have cancer in their bladder after treatment — and which do not. ...
News
New Program Will Improve Patient Access to Clinical Trials
A multidisciplinary team at Fox Chase Cancer Center has developed and tested a patient-centered education program designed to reduce barriers to clinical trial participation among kidney cancer patients.
News
This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve ...